TENEKTEPLASE: NEW POSSIBILITIES FOR SYSTEMIC THROMBOLYTIC THERAPY OF ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION

Abstract

Possibilities to use and advantages of a new tissue plasminogen activator (tenekteplase) in patients with acute coronary syndrome (ACS) with ST segment elevation are discussed. The main factor of tenekteplase successful implementation is the time. Comparative studies of tenekteplase and other tissue plasminogen activator are presented. Efficacy of thrombolytic therapy and percutaneous coronary interventions is compared. Data from multicenter randomized clinical trials about combined use of tenekteplase and enoxaparin and unfractionated heparin in the hospital is discussed. Data about safety of tenekteplase in treatment of ACS with ST segment elevation is given.

Keywords

• acute coronary syndrome with st segment elevation
• thrombolytic therapy
• tenekteplase